Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii

被引:40
作者
Esterly, John S. [1 ]
Richardson, Chad L. [1 ]
Eltoukhy, Noha S. [1 ,4 ]
Qi, Chao [2 ,3 ]
Scheetz, Marc H. [1 ]
机构
[1] Midwestern Univ Chicago, Coll Pharm, Dept Pharm Practice, Downers Grove, IL USA
[2] NW Mem Hosp, Clin Microbiol Lab, Chicago, IL 60611 USA
[3] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA
[4] Rush Univ, Med Ctr, Chicago, IL 60612 USA
关键词
Acinetobacter baumannii; antibiotics; beta-lactamases; genetic mechanisms; resistance; METALLO-BETA-LACTAMASE; OUTER-MEMBRANE PROTEIN; IN-VITRO ACTIVITIES; MULTIDRUG EFFLUX PUMP; AMINOGLYCOSIDE-RESISTANCE; MOLECULAR EPIDEMIOLOGY; CARBAPENEM RESISTANCE; CLINICAL STRAINS; ANTIBIOTIC-RESISTANCE; POLYMYXIN-B;
D O I
10.1345/aph.1P084
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To summarize published data identifying known genetic mechanisms of antibiotic resistance in Acinetobacter baumannii and the correlating phenotypic expression of antibiotic resistance. DATA SOURCES: MEDLINE databases (1966-July 15, 2010) were searched to identify original reports of genetic mechanisms of antibiotic resistance in A. baumannii. DATA SYNTHESIS: Numerous genetic mechanisms of resistance to multiple classes of antibiotics are known to exist in A. baumannii, a gram-negative bacterium increasingly implicated in nosocomial infections. Mechanisms may be constitutive or acquired via plasmids, integrons, and transposons. Methods of resistance include enzymatic modification of antibiotic molecules, modification of antibiotic target sites, expression of efflux pumps, and downregulation of cell membrane porin channel expression. Resistance to beta-lactams appears to be primarily caused by beta-lactamase production, including extended spectrum beta-lactamases (bla(TEM), bla(CTX-M), bla(KPC)), metallo-beta-lactamases (bla(IMP), bla(VIM), bla(SIM)), and most commonly, oxacillinases (bla(OXA)). Antibiotic target site alterations confer resistance to fluoroquinolones (gyrA, parC) and aminoglycosides (arm, rmf), and to a much lesser extent, beta-lactams. Efflux pumps (tet, ade, abe) contribute to resistance against beta-lactams, tetracyclines, fluoroquinolones, and aminoglycosides. Finally, porin channel deletion (carO, oprD) appears to contribute to beta-lactam resistance and may contribute to rarely seen polymyxin resistance. Of note, efflux pumps and porin deletions as solitary mechanisms may not render clinical resistance to A. baumannii. CONCLUSIONS: A. baumannii possesses copious genetic resistance mechanisms. Knowledge of local genotypes and expressed phenotypes for A. baumannii may aid clinicians more than phenotypic susceptibilities reported in large epidemiologic studies.
引用
收藏
页码:218 / 228
页数:11
相关论文
共 126 条
[1]   Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes [J].
Abbo, A. ;
Carmeli, Y. ;
Navon-Venezia, S. ;
Siegman-Igra, Y. ;
Schwaber, M. J. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2007, 26 (11) :793-800
[2]   Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System [J].
Adams, Mark D. ;
Nickel, Gabrielle C. ;
Bajaksouzian, Saralee ;
Lavender, Heather ;
Murthy, A. Rekha ;
Jacobs, Michael R. ;
Bonomo, Robert A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) :3628-3634
[3]   Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania [J].
Adams-Haduch, Jennifer M. ;
Paterson, David L. ;
Sidjabat, Hanna E. ;
Pasculle, Anthony W. ;
Potoski, Brian A. ;
Muto, Carlene A. ;
Harrison, Lee H. ;
Doi, Yohei .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (11) :3837-3843
[4]   Building a benchmark through active surveillance of intensive care unit-acquired infections: the Italian network SPIN-UTI [J].
Agodi, A. ;
Auxilia, F. ;
Barchitta, M. ;
Brusaferro, S. ;
D'Alessandro, D. ;
Montagna, M. T. ;
Orsi, G. B. ;
Pasquarella, C. ;
Torregrossa, V. ;
Suetens, C. ;
Mura, I. .
JOURNAL OF HOSPITAL INFECTION, 2010, 74 (03) :258-265
[5]  
[Anonymous], 2009, M100S19 CLIN LAB STA
[6]   In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak [J].
Appleman, MD ;
Belzberg, H ;
Citron, DM ;
Heseltine, PNR ;
Yellin, AE ;
Murray, J ;
Berne, TV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1035-1040
[7]   In Vitro Activities of Tigecycline, Minocycline, and Colistin-Tigecycline Combination against Multi- and Pandrug-Resistant Clinical Isolates of Acinetobacter baumannii Group [J].
Arroyo, Luis A. ;
Mateos, Ingeborg ;
Gonzalez, Veronica ;
Aznar, Javier .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1295-1296
[8]   Evaluation of the ability of a commercial system to identify Acinetobacter genomic species [J].
Bernards, AT ;
vanderToorn, J ;
vanBoven, CPA ;
Dijkshoorn, L .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (04) :303-308
[9]   First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy [J].
Bertini, Alessia ;
Giordano, Alessandra ;
Varesi, Paola ;
Villa, Laura ;
Mancini, Carlo ;
Carattoli, Alessandra .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2268-2269
[10]   Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia [J].
Betrosian, Alex P. ;
Frantzeskaki, Frantzeska ;
Xanthaki, Anna ;
Douzinas, Emmanuel E. .
JOURNAL OF INFECTION, 2008, 56 (06) :432-436